Prime Medicine (PRME) Payables (2021 - 2026)

Prime Medicine (PRME) has 6 years of Payables data on file, last reported at $12.3 million in Q1 2026.

• Quarterly Payables rose 22.94% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 22.94% YoY) and the FY2025 annual result came in at $8.9 million, down 21.71% from the prior year.
• Payables advanced to $12.3 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $19.5 million in Q4 2023 to a low of $4.1 million in Q3 2022.
• A 5-year average of $8.7 million and a median of $8.9 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables soared 350.99% — and 2024, when it slumped 61.56%.
• Tracing PRME's Payables over 5 years: stood at $4.3 million in 2022, then soared by 350.99% to $19.5 million in 2023, then slumped by 41.9% to $11.4 million in 2024, then retreated by 21.71% to $8.9 million in 2025, then jumped by 38.69% to $12.3 million in 2026.
• The last three Payables figures came in at $12.3 million (Q1 2026), $8.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.